Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study

MT Newswires Live13:38

Prescient Therapeutics (ASX:PTX) reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.

The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.

The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.

Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664999896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664999896","market":"hk","top_or_hot":-1,"title":"Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PTX.AU\">Prescient Therapeutics</a> (ASX:PTX) reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.</p><p>The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.</p><p>The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.</p><p>Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-02 13:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PTX.AU\">Prescient Therapeutics</a> (ASX:PTX) reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.</p><p>The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.</p><p>The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.</p><p>Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664999896","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664999896","pubTimestamp":1788327489,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Prescient Therapeutics  reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7067":"生物科技","LENZ":"Therapeutics","BK7508":"医药生物股","BK4007":"制药","PTX.AU":"PRESCIENT THERAPEUTICS LTD","BK4539":"次新股"},"translate_title":"Prescient Therapeutics 在癌症药物研究中达到剂量优化审查里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTX.AU":1,"LENZ":1.5},"content_text":"Prescient Therapeutics (ASX:PTX) reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664999896","isCrawlerRequest":true}